Journal of IiME Volume 3 Issue 1 www.investinme.org P PRROOFFIILLEESS ooff PPRREESSEENNTTEERRSS aatt tthhee IINNVVEESSTT iinn MMEE I INNTTEERRNNAATTIIOONNAALL MMEE//CCFFSS CCOONNFFEERREENNCCEE data. These data are then translated into diagnostic and treatment strategies that can be personalized” for each patient. This model can be extended to each physician such that data from individual cohorts or subgroups of patients can be entered into a fully secure/ international national database that can be queried by physicians anywhere in the world giving each physician tools with which to diagnose and treat patients with similar genetic, immune and pathogen profiles. We used this strategy to study more than 100 difficult and complicated CFS patients from a well-defined Nevada ME/CFS cohort resulting from outbreak of ME/CFS that occurred between 1984 and 1987. Immune profiling reveals immune defects including in T, B and NK cell compartments. These abnormalities are suggestive of a persistent infection and predicative of the development of lymphoma. Moreover using antibody microarrays to profile serum biomarkers in this cohort we have developed a five-cytokine/chemokine signature that can identify CFS patients from controls with 94% sensitivity and specificity. Viral microarray studies demonstrate persistent active herpes viruses, enteroviruses, adenoviruses and parvoviruses. Genetic profiling revealed HLA and killer immunoglobulin receptor (KIR) genotypes predictive of susceptible and protective genotypes in this cohort. Taken together these data suggest that this systems biology strategy can be developed diagnostically, for the development of serum biomarkers to stratify subgroups of ME/CFS patients for appropriate anti-inflammatory, antimicrobial and antiviral therapeutics. Additional links for Dr Mikovits: http://lib.bioinfo.pl/auth:Mikovits,J Example of other work: Epigenetic control during lymphoid development and immune responses: aberrant regulation, viruses, and cancer. Muegge K, Young H, Ruscetti F, Mikovits J. Ann N Y Acad Sci. 2003 Mar;983:55-70. Review. PMID: 12724212 [PubMed - indexed for MEDLINE] The Invest in ME International ME/CFS Conferences Invest in ME (Charity Nr. 1114035) Page 75/76
76 Publizr Home